Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO

Launched by BEIJING CHAO YANG HOSPITAL · Sep 25, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how a specific measurement called transpulmonary mechanical power can help predict the outcomes for patients with severe Acute Respiratory Distress Syndrome (ARDS) who are receiving a treatment known as venovenous extracorporeal membrane oxygenation (VV-ECMO). VV-ECMO is a life-support system that helps patients breathe when their lungs are severely compromised. Unfortunately, even with this advanced treatment, many patients still do not survive. The trial aims to see if understanding the mechanical power being used on the lungs can provide better insights into how well patients might do during their treatment.

To participate in the study, patients must be diagnosed with ARDS and currently receiving VV-ECMO support. However, there are some specific conditions that would exclude a patient from joining, such as having been on high-pressure ventilation for more than seven days or having certain severe medical conditions. If eligible, participants will be monitored closely to see how the transpulmonary mechanical power affects their recovery and overall prognosis. This research could help improve treatment strategies for future patients facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meet the diagnostic criteria of Berlin's definition for ARDS;
• • 2. Receiving VV-ECMO support.
• Exclusion Criteria:
• • 1. Patients had been on high pressure (Ppeak \>35 cm H2O) and a high fraction of inspired oxygen (FiO2\>0.8) ventilation for \>7 days;
• • 2. Patients had a contraindication to heparinization;
• • 3. Patients had an irreversible neurological injury;
• • 4. Patients had severe chronic lung disease with life expectancy \<6 months.